<DOC>
	<DOCNO>NCT00099502</DOCNO>
	<brief_summary>The purpose study determine - whether treatment Betaferon / Betaseron ( interferon beta-1b ) 500 microgram safe , tolerable efficacious treatment interferon beta-1b 250 microgram - whether treatment Betaferon / Betaseron ( interferon beta-1b ) tolerable efficacious treatment Copaxone ( Glatiramer Acetate ) 20 mg</brief_summary>
	<brief_title>BEYOND : Betaferon/Betaseron Efficacy Yielding Outcomes New Dose Multiple Sclerosis ( MS ) Patients</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Schering AG , Germany . Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc. , Schering AG Germany rename Bayer Schering Pharma AG , Germany . Bayer HealthCare Pharmaceuticals , Inc.and Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Female male patient Aged 1855 year Diagnosis RRMS ( RelapsingRemitting Multiple Sclerosis ) , EDSS score 0 5.0 Treatmentnaive IFNB Copaxone Neurological progression disease onset relapse Serious acute heart diseases History severe depression suicide attempt Serious acute liver , renal bone marrow dysfunction Monoclonal gammopathy Known allergy GadoliniumDTPA , IFNs ( Interferons ) , glatiramer acetate , human albumin mannitol Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Relapsing multiple sclerosis</keyword>
	<keyword>interferon beta 1b</keyword>
	<keyword>Betaferon</keyword>
	<keyword>Betaseron</keyword>
</DOC>